查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591893

人类胰岛素製剂市场：按胰岛素类型、输送装置、应用、分销管道分类 - 全球预测 2025-2030

Human Insulin Drugs Market by Insulin Type (Basal or Long-Acting Insulins, Biosimilar Insulins, Intermediate-Acting Insulin), Delivery Devices (Insulin Pens, Insulin Pumps, Insulin Syringes), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年人类胰岛素製剂市值为572.6亿美元，预计2024年将达620.2亿美元，复合年增长率为8.78%，到2030年将达到1032.2亿美元。

人类胰岛素产品市场包括用于调节糖尿病患者血糖值的胰岛素产品的开发、製造和分销。该系列包括多种形式的胰岛素，包括速效、短效、中效和长效，以满足不同的治疗需求和患者偏好。由于人口老化、久坐的生活方式和饮食习惯等因素，全球糖尿病盛行率不断上升，决定了对胰岛素的需求。该应用程式主要专注于 1 型和 2 型糖尿病的管理，最终用户包括医院、诊所和居家医疗机构。

主要市场统计
基准年[2023] 572.6亿美元
预测年份 [2024] 620.2亿美元
预测年份 [2030] 1032.2亿美元
复合年增长率（%） 8.78%

市场的关键成长要素包括胰岛素输送系统（如胰岛素笔、胰岛素帮浦和人工胰臟装置）的技术进步、患者依从性和疗效的提高等。在欧洲和美国等地区，监管支持导致人们更加关註生物相似药和具有成本效益的胰岛素製剂，创造了巨大的商机。公司应考虑投资下一代胰岛素研发和数位健康解决方案，以提高病人参与和个人化糖尿病管理策略。此外，向亚太地区和拉丁美洲等糖尿病人口不断增长的新兴市场扩张也提供了潜在的成长机会。

然而，市场面临严格的法规环境和与创新胰岛素疗法相关的高开发成本等限制。此外，定价压力和更便宜的学名药的存在正在挑战市场成长，并可能影响盈利。最佳创新领域包括超长效胰岛素製剂的开发、智慧胰岛素输送系统的开发以及用于即时血糖监测和胰岛素剂量的数位生态系统的整合。此外，病患教育和提高糖尿病管理意识是市场扩张的一条未被充分考虑的途径。总体而言，该市场的特点是快速创新和激烈竞争，导致公司专注于合作伙伴关係和创新产品平臺，以保持竞争力并满足不断变化的糖尿病治疗需求。

市场动态：揭示快速发展的人类胰岛素市场的关键市场洞察

供需的动态交互作用正在改变人类胰岛素市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球糖尿病患者数量不断增加
    • 提高糖尿病患者生物仿製胰岛素的可用性和采用率
    • 人类胰岛素给药系统的技术进展
  • 市场限制因素
    • 人类胰岛素製剂的不良健康影响及相关的高成本
  • 市场机会
    • 持续研究开发新化合物和治疗方法
    • 胰岛素配方可能的改进与进步
  • 市场挑战
    • 严格的核准规定和有限的供应

波特五力：驾驭人类胰岛素市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对人类胰岛素市场的影响

外部宏观环境因素对人类胰岛素製剂市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解人类胰岛素製剂市场竞争状况

对人类胰岛素製剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人类胰岛素製剂市场供应商绩效评估

FPNV定位矩阵是评估人类胰岛素製剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製人类胰岛素製剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对人类胰岛素製剂市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球糖尿病的盛行率正在上升
      • 提高糖尿病患者生物相似药胰岛素的可得性和采用率
      • 人类胰岛素给药系统的技术进展
    • 抑制因素
      • 对健康的不利影响和相关的高成本
    • 机会
      • 持续研究开发新化合物和治疗方法
      • 胰岛素配方的潜在改进和进步
    • 任务
      • 严格核准、限量供应监管标准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以胰岛素类型分類的人类胰岛素製剂市场

  • 基础或长效胰岛素
  • 胰岛素生物相似药
  • 中效胰岛素
  • 混合胰岛素
  • 速效胰岛素
  • 速效胰岛素

第七章人类胰岛素製剂市场分布（按设备）

  • 胰岛素笔
  • 胰岛素帮浦
  • 胰岛素注射器

第八章人类胰岛素製剂市场：依应用分类

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第九章人类胰岛素製剂市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十章北美和南美人类胰岛素製剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区人类胰岛素製剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲人胰岛素製剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 胰岛素製造商Genesis投资5000-6000万美元在海得拉巴建工厂
    • Humacyte 和 JDRF 合作开发产生胰岛素的生物血管胰腺来治疗第 1 型糖尿病
    • 礼来公司和 EVA Pharma 宣布建立合作伙伴关係，以加强非洲可持续获得负担得起的胰岛素
  • 战略分析和建议

公司名单

  • Albireo Pharma, Inc. by Ipsen
  • B. Braun Melsungen AG
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Eli Lilly and Company
  • Eris Lifesciences Ltd.
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Gulf Pharmaceutical Industries
  • Innova Life Sciences Private Limited
  • Lupin Limited
  • MannKind Corporation
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Shreya Life Sciences Pvt Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Limited
  • Zhuhai United Laboratories Co., Ltd.
Product Code: MRR-957C47F9221F

The Human Insulin Drugs Market was valued at USD 57.26 billion in 2023, expected to reach USD 62.02 billion in 2024, and is projected to grow at a CAGR of 8.78%, to USD 103.22 billion by 2030.

The human insulin drugs market encompasses the development, manufacturing, and distribution of insulin medications used to regulate blood sugar levels in people with diabetes. Its scope includes various forms such as rapid-acting, short-acting, intermediate-acting, and long-acting insulin, catering to different therapeutic needs and patient preferences. The necessity of insulin is dictated by the global rise in diabetes prevalence, driven by factors like aging populations, sedentary lifestyles, and dietary habits. Applications primarily focus on managing Type 1 and Type 2 diabetes, with end-users including hospitals, clinics, and homecare settings.

KEY MARKET STATISTICS
Base Year [2023] USD 57.26 billion
Estimated Year [2024] USD 62.02 billion
Forecast Year [2030] USD 103.22 billion
CAGR (%) 8.78%

Key growth influencers in the market include technological advancements in insulin delivery systems, such as insulin pens, pumps, and artificial pancreas devices, improving patient adherence and efficacy. The growing focus on biosimilars and cost-effective insulin options, driven by regulatory support in regions like Europe and the U.S., presents considerable opportunities. Companies should consider investing in research and development for next-generation insulin formulations and digital health solutions to increase patient engagement and personalized diabetes management strategies. Furthermore, expanding into emerging markets with rising diabetic populations, such as Asia-Pacific and Latin America, offers potential growth opportunities.

However, the market faces limitations, including stringent regulatory environments and high development costs associated with innovative insulin therapies. Additionally, market growth is challenged by pricing pressures and the presence of cheaper generic alternatives, which can affect profitability. The best areas for innovation include developing ultra-long-acting insulin varieties, smart insulin delivery systems, and integrating digital ecosystems for real-time glucose monitoring and insulin dosing. Also, enhancing patient education and awareness about diabetes management offers a less explored avenue for market expansion. Overall, as the market is characterized by rapid technological changes and strong competition, companies should focus on collaborative partnerships and innovative product pipelines to maintain a competitive edge and meet the evolving demands of diabetic care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Insulin Drugs Market

The Human Insulin Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of dibetic patient all over the globe
    • Increased availability and adoption of the biosimilar insulin among patients with diabetes
    • Technological advancements in human insulin drug delivery systems
  • Market Restraints
    • Adverse health impacts and associated high cost of human insulin drugs
  • Market Opportunities
    • Ongoing reserach activities for developments of new compounds and treatments
    • Potential improvements and advancement in the insulin formulations
  • Market Challenges
    • Stringent regulatory norms for approvals coupled with limited availability

Porter's Five Forces: A Strategic Tool for Navigating the Human Insulin Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Insulin Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Insulin Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Insulin Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Insulin Drugs Market

A detailed market share analysis in the Human Insulin Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Insulin Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Insulin Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Insulin Drugs Market

A strategic analysis of the Human Insulin Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Insulin Drugs Market, highlighting leading vendors and their innovative profiles. These include Albireo Pharma, Inc. by Ipsen, B. Braun Melsungen AG, Biocon Limited, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Eli Lilly and Company, Eris Lifesciences Ltd., Gan & Lee Pharmaceuticals Co., Ltd., Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries, Innova Life Sciences Private Limited, Lupin Limited, MannKind Corporation, Merck KGaA, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Shreya Life Sciences Pvt Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Limited, and Zhuhai United Laboratories Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Insulin Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Insulin Type, market is studied across Basal or Long-Acting Insulins, Biosimilar Insulins, Intermediate-Acting Insulin, Mixed Insulins, Rapid-Acting Insulin, and Short-Acting Insulin.
  • Based on Delivery Devices, market is studied across Insulin Pens, Insulin Pumps, and Insulin Syringes.
  • Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of dibetic patient all over the globe
      • 5.1.1.2. Increased availability and adoption of the biosimilar insulin among patients with diabetes
      • 5.1.1.3. Technological advancements in human insulin drug delivery systems
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health impacts and associated high cost of human insulin drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing reserach activities for developments of new compounds and treatments
      • 5.1.3.2. Potential improvements and advancement in the insulin formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory norms for approvals coupled with limited availability
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Insulin Drugs Market, by Insulin Type

  • 6.1. Introduction
  • 6.2. Basal or Long-Acting Insulins
  • 6.3. Biosimilar Insulins
  • 6.4. Intermediate-Acting Insulin
  • 6.5. Mixed Insulins
  • 6.6. Rapid-Acting Insulin
  • 6.7. Short-Acting Insulin

7. Human Insulin Drugs Market, by Delivery Devices

  • 7.1. Introduction
  • 7.2. Insulin Pens
  • 7.3. Insulin Pumps
  • 7.4. Insulin Syringes

8. Human Insulin Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Gestational Diabetes
  • 8.3. Type 1 Diabetes
  • 8.4. Type 2 Diabetes

9. Human Insulin Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Human Insulin Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Human Insulin Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Human Insulin Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Insulin Maker GeneSys to invest USD 50-60 mn to Set up Plant in Hyderabad
    • 13.3.2. Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes
    • 13.3.3. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Albireo Pharma, Inc. by Ipsen
  • 2. B. Braun Melsungen AG
  • 3. Biocon Limited
  • 4. Bristol-Myers Squibb Company
  • 5. Cadila Pharmaceuticals Limited
  • 6. Eli Lilly and Company
  • 7. Eris Lifesciences Ltd.
  • 8. Gan & Lee Pharmaceuticals Co., Ltd.
  • 9. Glenmark Pharmaceuticals Ltd.
  • 10. Gulf Pharmaceutical Industries
  • 11. Innova Life Sciences Private Limited
  • 12. Lupin Limited
  • 13. MannKind Corporation
  • 14. Merck KGaA
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Shreya Life Sciences Pvt Ltd.
  • 19. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 20. Torrent Pharmaceuticals Ltd.
  • 21. Wockhardt Limited
  • 22. Zhuhai United Laboratories Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. HUMAN INSULIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN INSULIN DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HUMAN INSULIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HUMAN INSULIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN INSULIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN INSULIN DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY BASAL OR LONG-ACTING INSULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY BIOSIMILAR INSULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY MIXED INSULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. HUMAN INSULIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. HUMAN INSULIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023